Compare Enveric Biosciences Inc (ENVB) vs TeraWulf Inc (WULF) Price & Performance

ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.

The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.

WULF trades at $14.40, down 3.81% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The company reported a net loss of -$661.42M in 2025, with revenue of $168.46M, and has missed earnings expectations in recent quarters. Analyst consensus remains strongly bullish with a $34.92 price target, supported by positive news on AI data center leasing trends.

The outlook for WULF hinges on its pivot to AI data center hosting, offering growth potential, but significant risks persist from deep losses, negative margins, and high debt. Investors should weigh analyst optimism against fundamental weaknesses and volatile cash flows.